证券日报网讯12月16日，优宁维（301166）在互动平台回答投资者提问时表示，根据公司章程的规定： 股东提出查阅股东人数等股东名册相关信息，应当向公司提供证明其持有公司股份的种类以及持股数量 的书面文件，公司经核实股东身份后按照股东的要求予以提供。故其他时点股东信息的查询，需提供上 述相关书面文件，并经公司核实股东身份后予以提供。 ...

针对上述提问，优宁维回应称："投资者您好，公司已通过参与产业基金，借助专业机构投研力量和自 身市场资源，围绕医疗健康等行业开展相关的投资业务。感谢您的建议，谢谢。" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 有投资者在互动平台向优宁维提问："冷总，公司股价长期破发，超募那么多资金只顾理财产品，为什 么不成立股权投资基金投资国家支持的高科技行业！" 来源：市场资讯 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-093 上海优宁维生物科技股份有限公司 关于注销募集资金专项账户的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海优宁维生物科技股份有限 公司首次公开发行股票注册的批复》（证监许可〔2021〕3556 号）同意注册， 并经深圳证券交易所同意，上海优宁维生物科技股份有限公司（以下简称"公司"） 首次公开发行人民币普通股（A 股）股票 2,166.6668 万股，每股面值为人民币 1.00 元，发行价格为人民币 86.06 元/股，募集资金总额为人民币 186,463.34 万元， 扣除发行费用人民币 26,911.62 万元（不含税）后，实际募集资金净额为人民币 159,551.73 万元。 上述募集资金已全部到账，天职国际会计师事务所（特殊普通合伙）已对上 述资金到位情况进行了审验，并出具了天职业字[2021]45819 号《验资报告》。 上述募集资金到账后，公司对募集资金的存放和使用进行专户管理，并与专 户银行、保荐机构签订了 ...

证券日报网讯12月4日，优宁维（301166）在互动平台回答投资者提问时表示，公司2025年开展了9次投 资者调研及2次投资者集体接待日活动。 ...

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

格隆汇12月1日丨优宁维(301166.SZ)公布，截至2025年11月30日，公司通过股份回购专用证券账户以集 中竞价交易方式累计回购公司股份80,400股，占公司总股本的0.09%，最高成交价为31.00元/股，最低成 交价为30.46元/股，支付的总金额为2,475,786元（不包含交易费用）。 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-092 上海优宁维生物科技股份有限公司 关于回购公司股份的进展公告 （1）自可能对本公司证券及其衍生品种交易价格产生重大影响的重大事项 发生之日或者在决策过程中，至依法披露之日内； 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 上海优宁维生物科技股份有限公司(以下简称"公司")于 2025 年 4 月 10 日召 开第四届董事会第四次会议、第四届监事会第四次会议，于 2025 年 5 月 13 日召 开 2024 年度股东大会，审议通过了《关于回购公司股份方案的议案》，同意公 司使用不低于人民币 1,500 万元（含本数），不高于人民币 3,000 万元（含本数） 的自有资金以集中竞价交易方式回购公司部分无限售条件的 A 股流通股，用于 注销并减少注册资本，回购价格不超过人民币 44 元/股（含本数，下同），回购 期限自公司 2024 年度股东大会审议通过本次回购股份方案之日起 12 个月内。具 体内容详见公司于 2025 年 4 月 14 日及 2025 年 5 月 13 日刊登在巨潮资讯网的《 ...

Core Insights - The stock of Uningwei increased by 1.19% on November 12, with a trading volume of 51.13 million yuan [1] - The company experienced a net financing outflow of 2.28 million yuan on the same day, indicating a low financing balance compared to the past year [1] - Uningwei's main business includes providing life science reagents, instruments, and technical services, with a revenue composition heavily weighted towards life science reagents [1] Financing and Trading Data - On November 12, Uningwei had a financing buy-in amount of 3.43 million yuan and a financing repayment of 5.71 million yuan, resulting in a net financing buy of -2.28 million yuan [1] - The total financing and securities lending balance as of November 12 was 56.88 million yuan, accounting for 1.98% of the circulating market value, which is below the 50th percentile of the past year [1] - Uningwei had no securities lending activity on November 12, with a lending balance of 0.00 shares, indicating a high level of inactivity in this area [1] Financial Performance - For the period from January to September 2025, Uningwei reported a revenue of 776 million yuan, a year-on-year decrease of 6.24%, and a net profit attributable to shareholders of -15.08 million yuan, a significant decline of 207.11% [2] - As of September 30, 2025, the number of Uningwei's shareholders was 9,893, a decrease of 13.19% from the previous period, while the average circulating shares per person increased by 15.19% to 5,753 shares [2] Dividend and Shareholding Information - Since its A-share listing, Uningwei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3] - As of September 30, 2025, the top ten circulating shareholders included a new shareholder, Nuoan Multi-Strategy Mixed A, holding 499,100 shares, ranking as the eighth largest circulating shareholder [3]

Core Viewpoint - The company You Ning Wei has shown a mixed performance in terms of stock trading and financial results, with a notable decrease in revenue and net profit year-on-year, while maintaining a significant presence in the life sciences sector [1][2]. Group 1: Stock Performance - On November 11, You Ning Wei's stock rose by 1.27%, with a trading volume of 33.29 million yuan [1]. - The financing buy-in amount on the same day was 3.30 million yuan, while the financing repayment was 3.03 million yuan, resulting in a net financing buy of 0.28 million yuan [1]. - As of November 11, the total financing and securities balance was 59.16 million yuan, accounting for 2.08% of the market capitalization, indicating a high level compared to the past year [1]. Group 2: Financial Performance - For the period from January to September 2025, You Ning Wei reported a revenue of 776 million yuan, representing a year-on-year decrease of 6.24% [2]. - The net profit attributable to the parent company was -15.08 million yuan, reflecting a significant year-on-year decline of 207.11% [2]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders for You Ning Wei was 9,893, a decrease of 13.19% from the previous period [2]. - The average number of circulating shares per person increased by 15.19% to 5,753 shares [2]. - The company has distributed a total of 182 million yuan in dividends since its A-share listing, with 138 million yuan distributed in the last three years [3].

Core Viewpoint - The financing activities of You Ning Wei (301166) show a positive trend with a net buying of 32.29 million yuan on November 10, 2025, indicating increased investor interest and confidence in the stock [1][2]. Financing Summary - On November 10, 2025, You Ning Wei had a financing buy-in of 2.34 million yuan and a financing repayment of 2.02 million yuan, resulting in a net financing increase of 0.32 million yuan, with a total financing balance of 58.88 million yuan [1]. - Over the past three trading days, the cumulative net buying reached 0.94 million yuan [1]. - The financing balance on November 10, 2025, represented 3.19% of the circulating market value [2]. Margin Trading Summary - The total margin trading balance on November 10, 2025, was 58.88 million yuan, reflecting an increase of 0.55% from the previous day [3]. - The margin trading balance has shown a consistent upward trend over the last few trading days, with notable increases on November 6 and November 7, 2025 [3].